n-acetyl cysteine + alpha lipoic acid + liposomal glutathione

This combination of N-acetyl cysteine (NAC), alpha lipoic acid (ALA), and liposomal glutathione is a specific antioxidant regimen utilized by Lykos Therapeutics (formerly MAPS Public Benefit Corporation) as a supportive adjunct in clinical protocols for MDMA-assisted psychotherapy. It is primarily used in trials such as the EAMP1 expanded access program for patients with treatment-resistant post-traumatic stress disorder (PTSD). The regimen is designed to provide neuroprotection by mitigating oxidative stress and potential serotonergic neurotoxicity associated with the metabolism of midomafetamine (MDMA). N-acetyl cysteine serves as a rate-limiting precursor for the synthesis of glutathione, the body's primary endogenous antioxidant. Alpha lipoic acid acts as a potent free radical scavenger and regenerator of other antioxidants, while liposomal glutathione provides a direct, highly bioavailable source of glutathione. This combination is typically administered post-session to facilitate physiological recovery and minimize the 'comedown' effects associated with MDMA administration.

Other names

Antioxidant regimenNeuroprotective stackMAPS antioxidant protocol